Table 2. Baseline and intervening time point demographic and clinical characteristics of individuals included in the gene expression analysis.
| Characteristic | Progressors | Non-Progressors | P-value | ||
|---|---|---|---|---|---|
| A) ETHIOPIA | N = 106 | N = 106 | P-value | ||
| Gender (female) | 72 | (67.9%) | 64 | (60.4%) | 0.25 |
| Age at baseline, mean (SD) | 50.2 | (13.0) | 50.8 | (15.1) | 0.74 |
| BMI at baseline, mean (SD) | 20.0 | (2.4) | 20.1 | (2.3) | 0.73 |
| Lash count, mean (SD) | 1.5 | (1.2) | 1.5 | (1.1) | 0.91 |
| Scarring severity at baseline A | |||||
| 1a | 0 | - | 0 | - | |
| 1b | 1 | (1.0%) | 1 | (1.0%) | |
| 1c | 14 | (13.2%) | 14 | (13.2%) | |
| 2 | 89 | (84.0%) | 89 | (84.0%) | |
| 3 | 2 | (1.9%) | 2 | (1.9%) | |
| Clinically inflamed (P2/P3) | |||||
| Baseline | 52 / 106 | (49.1%) | 34 / 106 | (32.1%) | 0.012 |
| 6-months | 23 / 87 | (26.4%) | 17 / 94 | (18.1%) | 0.18 |
| 12-months | 45 / 106 | (42.6%) | 24 / 106 | (22.6%) | 0.0021 |
| 18-months | 19 / 104 | (18.3%) | 13 / 104 | (12.5%) | 0.25 |
| Clinically inflamed, 1+ episode | 74 | (69.8%) | 46 | (43.4%) | 0.0001 |
| Proportion of examinations with inflammation (%) | 0.0028 | ||||
| 0% | 32 | (30.2%) | 60 | (56.6%) | |
| 25% | 27 | (25.5%) | 19 | (17.9%) | |
| 33% | 6 | (5.7%) | 0 | - | |
| 50% | 19 | (15.1%) | 10 | (9.4%) | |
| 66% | 4 | (3.8%) | 5 | (4.7%) | |
| 75% | 11 | (10.4%) | 7 | (6.6%) | |
| 100% | 10 | (9.4%) | 5 | (4.7%) | |
| B) TANZANIA | N = 97 | N = 97 | P-value | ||
| Gender (female) | 64 | (66.0%) | 55 | (56.7%) | 0.19 |
| Age at baseline, mean (SD) | 51.8 | (17.9) | 52.8 | (18.5) | 0.69 |
| BMI at baseline, mean (SD) | 21.3 | (2.9) | 21.7 | (3.3) | 0.36 |
| Scarring severity at baseline B | |||||
| 1a | 10 | (10.3%) | 10 | (10.3%) | |
| 1b | 32 | (33.0%) | 33 | (34.0%) | |
| 1c | 34 | (35.1%) | 38 | (39.2%) | |
| 2 | 12 | (12.4%) | 9 | (9.3%) | |
| 3 | 9 | (9.2%) | 7 | (7.2%) | |
| Clinically inflamed (P2/P3) | |||||
| Baseline | 30 / 97 | (30.9%) | 17 / 97 | (17.5%) | 0.029 |
| 6-months | 16 / 94 | (17.0%) | 7 / 94 | (7.5%) | 0.045 |
| 12-months | 12 / 89 | (13.5%) | 1 / 81 | (1.2%) | 0.0026 |
| 18-months | 5 / 83 | (6.0%) | 0 / 88 | - | 0.019 |
| Clinically inflamed, 1+ episode | 33 / 97 | (34.0%) | 22 / 97 | (22.7%) | 0.08 |
| Proportion of examinations with inflammation (%) | 0.051 | ||||
| 0% | 64 | (66.0%) | 75 | (77.3%) | |
| 25% | 10 | (10.3%) | 11 | (11.3%) | |
| 33% | 7 | (7.2%) | 8 | (8.3%) | |
| 50% | 3 | (3.1%) | 2 | (2.1%) | |
| 66% | 2 | (2.1%) | 1 | (1.0%) | |
| 75% | 5 | (5.2%) | 0 | - | |
| 100% | 6 | (6.2%) | 0 | - | |
(A) 212 Ethiopian participants; non-progressors were frequency matched on baseline scarring severity. (B) 194 Tanzanian participants; non-progressors were frequency matched on baseline scarring severity and age.
A Non-Progressors were frequency matched on baseline scarring to the Progressors.
B Non-Progressors were frequency matched on baseline scarring and age to the Progressors.